Adaptimmune Therapeutics PLC
NASDAQ:ADAP

Watchlist Manager
Adaptimmune Therapeutics PLC Logo
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Watchlist
Price: 0.04 USD
Market Cap: 10.6m USD

Gross Margin
Adaptimmune Therapeutics PLC

31.9%
Current
11%
Average
63.1%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
31.9%
=
Gross Profit
20.7m
/
Revenue
65.1m

Gross Margin Across Competitors

No Stocks Found

Adaptimmune Therapeutics PLC
Glance View

Market Cap
10.6m USD
Industry
Biotechnology

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. The company is headquartered in Abingdon, Oxfordshire and currently employs 494 full-time employees. The company went IPO on 2015-05-06. The Company’s Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. The Company’s proprietary platform enables it to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. The Company’s clinical trials include SPEARHEAD-1 Phase II Trial with afamitresgene autoleucel (afami-cel), SPEARHEAD-2 Phase II trial with afami-cel, SURPASS Phase I trial with ADP-A2M4CD8, ADP-A2AFP Phase I trial and Afami-cel Phase I trial radiation sub-study.

ADAP Intrinsic Value
Not Available
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
31.9%
=
Gross Profit
20.7m
/
Revenue
65.1m
What is the Gross Margin of Adaptimmune Therapeutics PLC?

Based on Adaptimmune Therapeutics PLC's most recent financial statements, the company has Gross Margin of 31.9%.

Back to Top